CTOs on the Move

The Center for Professional Innovation and Educa

www.cfpie.com

 
The Center for Professional Innovation and Education is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cfpie.com
  • 992 Old Eagle School Rd Ste 913
    Wayne, PA USA 19087
  • Phone: 610.688.1708

Executives

Name Title Contact Details

Similar Companies

Cardiff Oncology

Cardiff Oncology, Inc. is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.

Sonde Health

Sonde Health is a digital medicine company developing a voice-based technology platform with the potential to transform the way we monitor and diagnose mental and physical health.

ZYTO Corporation

ZYTO Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Hecker and Associates

Hecker and Associates is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abeona Therapeutics

Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company`s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company`s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases.